Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial

• Main Authors: Kathleen Mulligan, David V. Glidden, Peter L. Anderson, Albert Liu, Vanessa McMahan, Pedro Gonzales, Maria Esther Ramirez-Cardich, Sirianong Namwongprom, Piotr Chodacki, Laura Maria Carvalo De Mendonca, Furong Wang, Javier R. Lama, Suwat Chariyalertsak, Juan Vicente Guanira, Susan Buchbinder, Linda Gail Bekker, Mauro Schechter, Valdilea G. Veloso, Robert M. Grant, Lorena Vargas, Jorge Sanchez, Chiang Mai, Pongpun Saokhieo, Kerry Murphy, Hailey Gilmore, Sally Holland, Elizabeth Faber, John Duda, Linda Bewerunge, Elizabeth Batist, Christine Hoskin, Ben Brown, Rio De Janeiro, Carina Beppu-Yoshida, Marcellus Dias Da Costa, Sergio Carlos Assis De Jesus, Jose Roberto Grangeiro Da Silva, Roberta Millan, Brenda Regina De Siqueira Hoagland, Nilo Martinez Fernandes, Lucilene Da Silva Freitas, Beatriz Grinsztejn, Jose Pilotto, Lane Bushman, Jia Hua Zheng, Louis Anthony Guida, Brandon Kline, Pedro Goicochea, Jonathan Manzo, Robert Hance, Jeff McConnell, Patricia Defechereux, Vivian Levy, Malu Robles, Brian Postle, David Burns, James Rooney
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84938598621&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/54819
• Institution: Chiang Mai University

© 2015 The Author 2015. Background. Daily preexposure prophylaxis (PrEP) with oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) decreases the risk of human immunodeficiency virus (HIV) acquisition. Initiation of TDF decreases bone mineral density (BMD) in HIV-infected people. We report...